March 27, 2024 – Talk Bio

“#FierceMadness 2024: Best Biotech Name Tournament Round of 32 Results”

1 year ago talkbio0Tagged Beyfortus, biotech, Biotech Name, Daybue, drug names, Fierce, FierceMadness, Marketing Suitability, Mounjaro, results, Round shape, Tournament, Wainua

#FierceMadness, Best Biotech Name Tournament, Round of 32 Results, Drug Names, Marketing Suitability, Mounjaro, Daybue, Beyfortus, Wainua, Fierce Biotech, Voting Results

Pfizer Continues FDA Approval Expectations for Sickle Cell Disease Therapy Despite Terminating One Phase 3 Trial

1 year ago talkbio0Tagged Antibody/, Approval/, Disease/, Inclacumab/, monoclonal, Pfizer/, Program/, terminated - RoleStatus, Thrive, Trial/ Poor Accrual, United States Food and Drug Administration

Pfizer/ Sickle Cell Disease/ FDA Approval/ Inclacumab/ THRIVE Program/ Monoclonal Antibody/ Terminated Trial/ Poor Accrual

Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment

1 year ago talkbio0Tagged Anemia, Sickle Cell, ClinicalTrials.gov, Grail, inclacumab, Pfizer, Phase 3 Clinical Trials, Poor Accrual, Recruitment Challenges, THRIVE Program

Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies

Praxis’ Mid-Stage Triumph Propels Advancement of Novel Epilepsy Drug

1 year ago talkbio0Tagged Adult Focal Onset, concept, Efficacy Study, Epilepsy, Functionally Selective Small Molecule,, Hyperexcitable State, Phase IIa, PRAX-628, Praxis Precision Medicines, Sodium Channel, Success

Praxis Precision Medicines, PRAX-628, Functionally Selective Small Molecule, Hyperexcitable State of Sodium Channels, Adult Focal Onset Epilepsy Treatment, Phase IIa Proof of Concept Study Success, Second Half of 2024 Efficacy Study Planned